## SHARE CAPITAL

Our authorized share capital as of the Latest Practicable Date was US\$50,000 divided into (a) 99,548,718,000 Ordinary Shares of US\$0.0000005 each, (b) 451,282,000 Preferred Shares of par value US\$0.0000005 each.

As of the Latest Practicable Date, the issued share capital consisted of 1,718,316,000 Ordinary Shares of par value of US\$0.0000005 each and 400,000,000 Preferred Shares of par value of US\$0.0000005 each.

The authorized share capital of our Company immediately before the Global Offering is US\$50,000, divided into 100,000,000,000 Shares with a nominal values of 0.0000005 per Share.

Assuming the Over-allotment Option is not exercised and without taking into account of any Shares to be issued upon the exercise of share options granted under the Pre-IPO Share Option Scheme and any Shares which may be issued under the Post-IPO RSU Scheme, the share capital of our Company upon completion of the Global Offering will be as follows:

Description of Shares	Number of Shares	Aggregate nominal value of Shares (USD)	Approximately percentage of issued share capital (%)
Shares in issue <sup>(1)</sup>	2,118,316,000	1,059.158	75
Shares to be issued under the Global Offering	706,106,000	353.053	25
Total	2,824,422,000		100

Note:

Assuming the Over-allotment Option is exercised in full and without taking into account of any Shares to be issued upon the exercise of share options granted under the Pre-IPO Share Option Scheme and any Shares which may be issued under the Post-IPO RSU Scheme, the share capital of our Company upon completion of the Global Offering will be as follows:

Description of Shares	Number of Shares	Aggregate nominal value of Shares (USD)	Approximately percentage of issued share capital (%)
Shares in issue	2,118,316,000	1,059.158	74.82
Shares to be issued under the Global Offering Shares to be issued upon the full exercise of the	706,106,000	353.053	24.94
Over-allotment Option	6,914,000	3.457	0.24
Total	2,831,336,000		100

## **ASSUMPTIONS**

The above tables assume that the Global Offering becomes unconditional and Shares are issued pursuant to the Global Offering. It takes no account of any Shares to be issued upon the exercise of any share options granted under the Pre-IPO Share Option Scheme or any Shares which may be issued or repurchased by us pursuant to the general mandates granted to our Directors to issue or repurchase Shares as described below.

## **RANKING**

The Offer Shares are ordinary shares in the share capital of our Company and rank equally with all Shares currently in issue or to be issued, in particular, will rank in full for all dividends or other distributions declared, made or paid on the Shares in respect of a record date which falls after the date of this prospectus.

<sup>(1)</sup> It includes 1,718,316,000 Shares in issue as of the Latest Practicable Date, 400,000,000 Shares to be issued upon conversion of all Series A Preferred Shares on a one-for-one basis.

## SHARE CAPITAL

#### **GENERAL MANDATE**

Our Directors have been granted a general unconditional mandate to allot, issue and deal with Shares with an aggregate nominal value of not more than the sum of:

- (i) 20% of the aggregate nominal value of the share capital of our Company in issue immediately following completion of the Global Offering; and
- (ii) the aggregate nominal value of share capital of our Company repurchased by our Company (if any) under the general mandate to repurchase Shares referred to below.

This mandate will expire at the earliest of:

- (i) the conclusion of our Company's next annual general meeting; or
- (ii) when varied, revoked or renewed by an ordinary resolution of our Shareholders in a general meeting.

Please refer to the section headed "Statutory and General Information — Further Information about Our Company — 5. Written Resolutions of the Shareholders Passed on March 18, 2014" in Appendix IV to this prospectus for details of this general mandate.

#### GENERAL MANDATE TO REPURCHASE SHARES

Our Directors have been granted a general unconditional mandate to exercise all the powers of our Company to repurchase Shares with a total nominal value of not more than 10% of the aggregate nominal amount of the share capital of our Company in issue or to be issued immediately following completion of the Global Offering.

This mandate only relates to repurchases made on the Hong Kong Stock Exchange, or any other approved stock exchange(s) on which the Shares are listed (and which is recognized by the SFC and the Hong Kong Stock Exchange for this purpose), and which are made in accordance with all applicable laws and/or requirements of the Listing Rules. A summary of the relevant Listing Rules is set out in "Statutory and General Information — Repurchase of Our Shares" in Appendix IV to this prospectus.

This mandate will expire at the earliest of:

- (i) the conclusion of our Company's next annual general meeting; or
- (ii) when varied, revoked or renewed by an ordinary resolution of our Shareholders in a general meeting.

Please refer to the section headed "Statutory and General Information — Further Information about the Company — 5. Written Resolutions of the Shareholders Passed on March 18, 2014" in Appendix IV to this prospectus for details of this repurchase mandate.

# PRE-IPO SHARE OPTION SCHEME

The Pre-IPO Share Option Scheme was adopted on June 18, 2010. Please refer to the section headed "Statutory and General Information — Pre-IPO Share Option Scheme" in Appendix IV to this prospectus for details.

### Pre-IPO RSU SCHEME

The Pre-IPO RSU Scheme was adopted on September 30, 2013. Please refer to the section headed "Statutory and General Information — Pre-IPO RSU Scheme" in Appendix IV to this prospectus for details.

## **Post-IPO RSU SCHEME**

The Post-IPO RSU Scheme was conditionally adopted pursuant to the written resolutions of the Shareholders of our Company passed on March 18, 2014. As of the Latest Practicable Date, no Shares have been issued pursuant to the Post-IPO RSU Scheme. Please refer to the section headed "Statutory and General Information — Post-IPO RSU Scheme" in Appendix IV to this prospectus for details.